
Elevance Health, Inc. company profile
$429.69−0.05%Close 13 Nov 2026 · Market value $96.13B
About Elevance Health, Inc.
Elevance Health is a health company that provides medical, pharmacy, and behavioral health services through managed care health plans and related businesses. It serves approximately 45.2 million medical members as of December 31, 2025, across Individual, Employer Group, Medicaid, and Medicare markets, and provides administrative and fee-based services to customers including self-funded employers and unaffiliated health plans. Its operations are organized into Health Benefits, CarelonRx (pharmacy services), Carelon Services (care management, behavioral health, and analytics), and Corporate & Other segments. The company is an independent licensee of the Blue Cross and Blue Shield Association and is licensed to conduct insurance operations in all 50 states, the District of Columbia, and Puerto Rico. It also provides services to the federal government, including administration of the Federal Employee Program.
A summary of the business section of the company's latest annual report, filed 6 Feb 2026.
Company facts
| Ticker | ELV · NYSE |
|---|
| Sector | Insurance |
|---|
| Industry | Managed Health Care |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 1156039 |
|---|
| Latest annual report | 10-K, filed 6 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Gail K. Boudreaux | President and CEO · Director | 443K | Open-market purchase, 17 Jul 2026 |
|---|
| Peter D. Haytaian | EVP & Pres Carelon & CarelonRx | 118K | Shares withheld for tax, 3 Mar 2026 |
|---|
| Felicia F. Norwood | EVP &Chief Health Benefits Ofr | 97.4K | Shares withheld for tax, 3 Mar 2026 |
|---|
| Morgan Kendrick | EVP & President, Commercial | 40.2K | Open-market sale, 6 Mar 2026 |
|---|
| Mark Kaye | EVP & CFO | 23.0K | Open-market sale, 22 Oct 2026 |
|---|
| Lewis Hay, III | Director | 11.5K | Grant or award, 13 May 2026 |
|---|
| Robert L. Dixon, Jr. | Director | 10.3K | Open-market sale, 11 Jun 2026 |
|---|
| R. Kerry Clark | Director | 9.6K | Grant or award, 14 May 2025 |
|---|
| Ramiro G. Peru | Director | 9.3K | Open-market purchase, 17 Jul 2026 |
|---|
| Ryan M. Schneider | Director | 6.6K | Grant or award, 13 May 2026 |
|---|
| Antonio F. Neri | Director | 4.9K | Grant or award, 13 May 2026 |
|---|
| Bahija Jallal | Director | 4.8K | Grant or award, 13 May 2026 |
|---|
| Susan D. DeVore | Director | 3.5K | Grant or award, 13 May 2026 |
|---|
| Deanna D. Strable | Director | 1.6K | Grant or award, 13 May 2026 |
|---|
| Steven H. Collis | Director | 639 | Grant or award, 13 May 2026 |
|---|
| LAVU RATNAKAR | EVP & Chief Digital Info Ofr | — | Open-market sale, 5 Nov 2026 |
|---|
| Wessling Erin M | EVP & Chief Legal Officer | — | Shares withheld for tax, 3 Sep 2026 |
|---|
| Craig Ryan R | EVP & Chief HR Officer | — | Shares withheld for tax, 2 Sep 2026 |
|---|
| Penczek Ronald W | CAO & Controller | — | Open-market sale, 12 Jun 2026 |
|---|
| Amy W. Schulman | Director | — | Grant or award, 13 May 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
ELV in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.